
Loading, please wait...

Loading, please wait...

Psoriasis presents as a chronic inflammatory skin condition that significantly impacts patient quality of life. Current clinical management often remains unsatisfactory due to persistent adverse effects and unmet needs. However, researchers have recently focused on **TRP channel psoriasis therapy** as a transformative approach to treatment. These Transient Receptor Potential (TRP) channels serve as non-selective cation sensors within the skin. Consequently, they regulate critical processes such as keratinocyte proliferation and immune cell infiltration. Furthermore, evidence suggests that altered expression of these channels contributes directly to psoriatic lesions.
Multiple TRP subtypes play distinct roles in the pathogenesis of this disease. Specifically, patients often show altered levels of vanilloid subtypes, including TRPV1, TRPV3, TRPV4, and TRPV6. Moreover, the canonical TRPC6 and melastatin TRPM8 channels influence cellular signaling. These channels stimulate sensory neurons and drive the activation of T lymphocytes and macrophages. Therefore, modulating these specific pathways could halt the cycle of hyperproliferation and inflammation. Additionally, the pharmacological targeting of these channels offers a path toward more efficacious and safer dermatological interventions.
The therapeutic potential of modulating these channels is already visible in existing treatments. For example, some topical pharmacotherapies and phototherapies inadvertently activate TRPV1 and TRPA1, causing side effects. Conversely, the repeated application of the TRPV1 agonist capsaicin induces channel desensitization. This process effectively reduces both pruritus and the clinical severity of psoriasis. Thus, developing precise pharmacological modulators represents a promising strategy for future care. Emerging studies continue to validate these channels as viable targets for novel drug development. In conclusion, the transition toward TRP-focused treatments may finally address the systemic complexities of psoriatic disease.
TRP channels are cellular sensors that control the flow of cations into cells. In psoriasis, they are overexpressed or dysfunctional, leading to excessive skin cell growth and immune system overactivity.
Capsaicin acts as a TRPV1 agonist. Repeated treatment desensitizes the channel, which reduces the inflammatory response and alleviates the intense itching often associated with psoriatic plaques.
Researchers aim to develop TRP modulators that target specific cellular pathways. This precision may offer a better safety profile compared to the broad immunosuppression or skin-thinning risks associated with long-term steroid use.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
da Silva AM et al. Role of transient receptor potential channels on pathogenesis and treatment of psoriasis. Inflammopharmacology. 2026 Feb 14. doi: 10.1007/s10787-025-02095-0. PMID: 41689746.
Riol-Blanco L, et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. Nature. 2014;510(7506):548-552.
Ozcan O, et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in patients with psoriasis. Adv Dermatol Allergol. 2021;38(4):645-651.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A review of TRP channels in psoriasis, highlighting subtypes like TRPV1 and TRPC6 as targets for novel, safer, and more effective dermatological treatments....
6 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today